Senzime AB (publ) (STO:SEZI)

Market Cap	688.51M
Revenue (ttm)	58.48M
Net Income (ttm)	-118.73M
Shares Out	133.17M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	33,435
Average Volume	132,542
Open	5.16
Previous Close	5.17
Day's Range	5.09 - 5.17
52-Week Range	4.97 - 9.60
Beta	0.63
RSI	38.76
Earnings Date	Apr 24, 2025

About Senzime AB

Senzime AB (publ), a medical device company, develops, manufactures, and markets algorithm-powered patient monitoring systems to increase patient safety during and after surgery in Europe and the United States. It offers TetraGraph, a quantitative neuromuscular transmission monitor, which supports neuromuscular blockade management from induction to recovery; and ExSpiron, a non-invasive monitoring system that uses bioelectrical impedance to measure the tissue’s opposition to carrying an alternating electrical current. The company has a strategi...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1999
• Employees: 52
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SEZI

Financial Performance

In 2024, Senzime AB's revenue was 58.48 million, an increase of 63.55% compared to the previous year's 35.75 million. Losses were -118.73 million, -11.50% less than in 2023.